Ph 2 trial of botensilimab (BOT), balstilimab (BAL) & agenT-797 in GEJ cancer shows 77% DCR and long-term survival beyond 20 months in heavily pretreated patients April 21, 2026
Imfinzi approved in the EU in patients with early gastric and gastroesophageal cancers March 17, 2026
Results announced from Ph 3 study of Anbenitamab (KN026) in HER2+ve gastric or gastroesophageal junction cancer (GC/GEJ) February 1, 2026
Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers February 1, 2026
Ph 1/2a Data of IMC002 Highlighted a Durable Complete Response Beyond 1 Year and a 66.7% ORR in Advanced GC/GEJ January 18, 2026
VYLOY™ (zolbetuximab) + Chemo Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses January 11, 2026
NDA for savolitinib for locally advanced/metastatic GC/GEJ adenocarcinoma patients with MET amplification accepted and granted priority review by the China NMPA December 30, 2025
Cadonilimab Receives FDA Clearance for Global Ph 3 1L Gastric Cancer Trial vs. Nivolumab December 15, 2025
Updated Efficacy Data from Ph 1/2 Transtar102 Trial of Osemitamab + Nivolumab and CAPOX in 1L G/GEJ Cancer Presented December 9, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with early gastric/GEJ cancers December 2, 2025
First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer November 4, 2025
Initial clinical data for BDC-4182 Ph 1 dose escalation study now expected in 3Q 2026 October 7, 2025
NMPA accepts NDA for KN026 in patients with HER2+ve locally advanced, recurrent, or metastatic gastric or GEJ cancer September 16, 2025
ATG-022 Granted Breakthrough Therapy Designation for the Treatment of Gastric/GEJ Adenocarcinoma August 26, 2025
Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and GEJ cancers July 29, 2025
CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the 1L Treatment of Gastric/GEJ Cancer June 17, 2025
Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis May 6, 2025
Imfinzi-based regimen demonstrated statistically significant and clinically meaningful EFS improvement in resectable early-stage G/GEJ cancers March 11, 2025
GEMSTONE-303 article published in JAMA, highlighting efficacy of sugemalimab + CAPOX vs placebo + CAPOX as 1L treatment for patients with unresectable locally advanced/metastatic G/GEJ adenocarcinoma with PD-L1 CPS ≥5 March 4, 2025
European Commission approves VYLOY (zolbetuximab) + chemo combo for 1L HER2-neg, CLDN 18.2 +ve gastric/GEJ adenocarcinoma September 25, 2024
